Metastatic pancreatic cancer (PC) has a dismal 5-year survival rate of 2% due to limited chemotherapy, lack of immunotherapy options, and high drug resistance. The tumor-immune microenvironment (TIME) in PC, marked by dense desmoplasia, inactive anti-cancer T-cells, and immunosuppressive regulatory T-cells (Tregs...
In Hwan Park, G. Botta, Shawn A. Abeynaike et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of approximately 13% and remains largely resistant to immunotherapy because its dense fibrotic stroma restricts drug penetration, and its immunosuppressive tumor microenvironment (TME) limits anti-tumor immunity. Novel strategies are urgently needed t...
Shawn A. Abeynaike, In Hwan Park, Ashley Martinez et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PCAD) remains one of the deadliest cancers with minimal treatment options, highlighting the need for more effective immunotherapeutic strategies capable of overcoming its highly immunosuppressive tumor microenvironment. Tumor penetrating peptides such as iRGD enhance the delivery and...
M. Harari, In Hwan Park, Shawn A. Abeynaike et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.